Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M.
The full lawsuit, which was filed in a Delaware court, is sealed. A court filing from Sage (